KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Emergent BioSolutions (EBS) Free Cash Flow (2016 - 2026)

Emergent BioSolutions has reported Free Cash Flow over the past 17 years, most recently at -$36.2 million for Q1 2026.

For Q1 2026, Free Cash Flow fell 185.04% year-over-year to -$36.2 million; the TTM value through Mar 2026 reached $145.5 million, up 23.83%, while the annual FY2025 figure was $169.0 million, 197.54% up from the prior year.
Free Cash Flow for Q1 2026 was -$36.2 million at Emergent BioSolutions, down from $86.0 million in the prior quarter.
Over five years, Free Cash Flow peaked at $175.6 million in Q4 2022 and troughed at -$191.8 million in Q1 2023.
A 5-year average of -$6.6 million and a median of -$12.7 million in 2025 define the central range for Free Cash Flow.
Biggest five-year swings in Free Cash Flow: plummeted 678.64% in 2024 and later surged 207.23% in 2025.
Year by year, Free Cash Flow stood at $175.6 million in 2022, then plummeted by 105.87% to -$10.3 million in 2023, then plummeted by 678.64% to -$80.2 million in 2024, then surged by 207.23% to $86.0 million in 2025, then crashed by 142.09% to -$36.2 million in 2026.
Business Quant data shows Free Cash Flow for EBS at -$36.2 million in Q1 2026, $86.0 million in Q4 2025, and -$10.0 million in Q3 2025.